Quagliariello et al., in 2019, investigated the potential cardiotoxic and pro-inflammatory effects of combining Pembrolizumab and Trastuzumab, two medications used in the treatment of cancer, particularly for HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.